Recent dip adds to Zimmer’s appeal

Article Excerpt

On February 5, 2021, Zimmer Biomet announced it would spin off its Spine and Dental businesses as a publicly traded company. The news helped push the stock up to $180 in April, but it is now down 19% from that peak. That’s due to concerns the spread of the Delta variant of COVID-19 will once again force hospitals to postpone orthopedic surgeries. However, spinoffs tend to work out well for both the new firm and its former parent. We feel investors with a long-term horizon should take advantage of the lower price to buy Zimmer ahead the spinoff. ZIMMER BIOMET HOLDINGS INC. $146 is a spinoff buy. The company (New York symbol ZBH; Manufacturing Sector; Shares outstanding: 208.8 million; Market cap: $30.5 billion; Dividend yield: 0.7%; Takeover Target Rating: Medium; www.zimmerbiomet.com) manufactures orthopedic reconstructive implants and surgical equipment for orthopedic surgeries. Zimmer has the largest market share for reconstructive implants in the U.S. Overall revenue rose 3.9%, from $7.68 billion in 2016…